| Literature DB >> 35355811 |
Nico Fricke1, Krishnan Raghunathan1, Ajit Tiwari1, Katherine M Stefanski2, Muthuraj Balakrishnan3, Alex G Waterson4, Ricardo Capone1, Hui Huang2, Charles R Sanders2, Joshua A Bauer2,5, Anne K Kenworthy1.
Abstract
Plasma membrane organization profoundly impacts cellular functionality. A well-known mechanism underlying this organization is through nanoscopic clustering of distinct lipids and proteins in membrane rafts. Despite their physiological importance, rafts remain a difficult-to-study aspect of membrane organization, in part because of the paucity of chemical tools to experimentally modulate their properties. Methods to selectively target rafts for therapeutic purposes are also currently lacking. To tackle these problems, we developed a high-throughput screen and an accompanying image analysis pipeline to identify small molecules that enhance or inhibit raft formation. Cell-derived giant plasma membrane vesicles were used as the experimental platform. A proof-of-principle screen using a bioactive lipid library demonstrates that this method is robust and capable of validating established raft modulators including C6- and C8-ceramide, miltefosine, and epigallocatechin gallate as well as identifying new ones. The platform we describe here represents a powerful tool to discover new chemical approaches to manipulate rafts and their components.Entities:
Year: 2022 PMID: 35355811 PMCID: PMC8961798 DOI: 10.1021/acscentsci.1c01058
Source DB: PubMed Journal: ACS Cent Sci ISSN: 2374-7943 Impact factor: 18.728
Figure 1Principles underlying the high-content imaging screen and data analysis pipeline. (a) The addition of small molecules can hypothetically enhance (magenta line), impede (green line), or have no effect on (black line) the ability of GPMVs to undergo phase separation. These outcomes can be distinguished by comparing the percentage of phase-separated vesicles observed under control and experimental conditions at a single temperature (dotted blue line). (b–d) Representative high-content image of HeLa cell-derived GPMVs labeled with DiD (magenta) and NBD-DSPE (green) shown at increasingly higher magnifications. Scale bars: (b) 20 μm, (c) 20 μm, and (d) 5 μm. (e–j) Example of how angular phase preference coefficients pang(ϕ) are measured as a function of angle ϕ and used to discern single phase and phase-separated GPMVs. (e–g) Example of a single phase GPMV, together with a plot and histograms of its corresponding angular phase preference coefficients. (h–j) Example of a phase-separated GPMV, together with a plot and histograms of its angular phase preference coefficients. Scale bars (e, h): 5 μm.
Figure 2Results and validation of HTS for compounds that impact GPMV phase behavior. Histograms of (a) percent phase-separated vesicles and (b) Pordered for NBD-DSPE across all wells for one representative screen. (c) Z-scores for percentage of phase-separated vesicles across three independent screens performed on different days to test reproducibility. Vertical lines demarcate the position of individual plates in each screen. Each data point corresponds to measurements from an individual well (single compound). Compounds with Z-scores >2 are shown in blue, and compounds with Z-scores <−2 are shown in red. (d) Plot comparing the average Z-scores for Pordered of NBD-DSPE versus the average Z-scores for the percentage of phase-separated vesicles versus for each compound across all screens. The identities of several hits are indicated on the graph. (e) Dose–response curves for two representative hits, TLCK and C6-ceramide. Data represent the mean ± SD from 2 independent experiments performed in duplicate. Insets show structures of TLCK and C6-ceramide. (f) Impact of C6-ceramide and TLCK on ΔTmisc. See Figure S7 for examples of curves used to calculate ΔTmisc. Data represent the mean ± SD from 2 independent experiments. Abbreviations in panel d are as follows: TOFA, 5-(tetradecyloxy)-2-furancarboxylic acid; 2-thio-PAF, 1-O-hexadecyl-2-deoxy-2-thio-S-acetyl-sn-glyceryl-3-phosphorylcholine; TLCK, Nα-tosyl-l-lysyl chloromethyl ketone; EGCG, (−)-epigallocatecatchin gallate; N-St. taurine, N-stearoyl taurine; 2-O-methyl PAF 16, 1-O-hexadecyl-2-O-methyl-sn-glyceryl-3-phosphorylcholine.
Compounds That Significantly Alter % Phase-Separated GPMVs
| chemical name | CasRn | effect on % phase-separated vesicles | ALogP | function | |
|---|---|---|---|---|---|
| TOFA | 54857-86-2 | ↓ | –3.41 | 6.85 | noncytotoxic inhibitor of acetyl-CoA carboxylase and fatty acid synthesis |
| 2-thio-PAF | 96801-55-7 | ↓ | –3.15 | 4.02 | isoteric analogue of platelet activating factor |
| C6 ceramide (d18:1/6:0) | 124753-97-5 | ↓ | –3.01 | 6.88 | cell permeable analogue of naturally occurring ceramide |
| C8 ceramide (d18:1/8:0) | 74713-59-0 | ↓ | –2.87 | 7.79 | cell permeable ceramide analogue |
| ciglitazone | 74772-77-3 | ↓ | –2.73 | 4.53 | antidiabetic drug; potent and selective PPARγ ligand |
| oleyl trifluoromethyl ketone | 177987-23-4 | ↓ | –2.65 | 8.05 | analogue of oleic acid |
| OMDM-1 | 616884-62-9 | ↓ | –2.62 | 7.59 | endocannabinoid analogue; inhibitor of arachidonoyl ethanolamide uptake |
| 94608-23-8 | ↓ | –2.45 | 3.77 | antioxidant found in grapes and red wine with antiproliferative, antineoplastic, and antiangiogenic activities | |
| 11(Z),14(Z)-eicosadienoic acid | 2091-39-6 | ↓ | –2.15 | 7.33 | uncommon naturally occurring polyunsaturated fatty acid |
| (2S)-OMPT | 1217471-69-6 | ↓ | –2.12 | 7.27 | selective agonist of the lysophosphatidic acid 3 (LPA3) receptor |
| O-1602 | 317321-41-8 | ↓ | –2.10 | 4.79 | abnormal cannabidiorcin; agonist of G-protein coupled receptor 55 |
| 119567-63-4 | ↓ | –2.09 | 5.79 | metabolite of sphingosine and an inhibitor of sphingosine kinase | |
| SU6656 | 330161-87-0 | ↓ | –2.06 | 2.62 | selective inhibitor of Src kinases |
| PAF C-16 | 74389-68-7 | ↓ | –2.00 | 3.46 | platelet activating factor C-16; mediates neutrophil migration and reactive oxygen species production |
| TLCK hydrochloride | 4238-41-9 | ↑ | 6.73 | 2.18 | nonselective proteinase inhibitor |
| (−)-epigallocatechin gallate | 989-51-5 | ↑ | 4.33 | 3.10 | phenol found in green and black tea with diverse biological activities |
| 63155-80-6 | ↑ | 3.21 | 6.29 | amino-acyl endocannabinoid | |
| XAV939 | 284028-89-3 | ↑ | 2.33 | 3.68 | tankyrase inhibitor |
| 83982-06-3 | ↑ | 2.19 | 5.38 | amino-acyl endocannabinoid | |
| 8-piperazin-1-yl-isoquinoline (hydrochloride) | 936643-79-7 | ↑ | 2.14 | 1.17 | synthetic intermediate used for pharmacological synthesis |
| thio-miltefosine | 943022-11-5 | ↑ | 2.12 | 4.47 | analogue of miltefosine, an inhibitor of phosphocholine cytidylyl transferase (CTP) with antimetastatic properties |
Abbreviations: TOFA, 5-(tetradecyloxy)-2-furancarboxylic acid; 2-thio-PAF, 1-O-hexadecyl-2-deoxy-2-thio-S-acetyl-sn-glyceryl-3-phosphorylcholine; OMDM-1, (S)-N-(1-(4-hydroxyphenyl)-2-hydroxyethyl) oleamide; (2S)-OMPT, 9Z-octadecenoic acid, (2S)-3-[(hydroxymercaptophosphinyl)oxy]-2-methoxypropyl ester, triethyl ammonium salt (1:2); O-1602, 5-methyl-4-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-1,3-benzenediol; SU6656, 2,3-dihydro-N,N-dimethyl-2-oxo-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]-1H-indole-5-sulfonamide; PAF C-16, platelet activating factor C-16 or 1-O-hexadecyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine; TLCK= Nα-tosyl-Lys chloromethyl ketone; XAV939, 3,5,7,8-tetrahydro-2-[4-(trifluoromethyl)phenyl]-4H-thiopyrano[4,3-d]pyrimidin-4-one.
As reported in the Cayman product information.
Compounds That Significantly Alter NBD-DSPE Raft Phase Preference
| chemical name | CasRn | effect on | ALogP | function | |
|---|---|---|---|---|---|
| CAY10444 | 298186-80-8 | ↓ | –2.04 | 2.05 | selective antagonist of the S1P3/EDG3 receptor, a member of a family of G-protein coupled receptors that bind sphingosine-1 phosphate (S1P) |
| FR122047 (hydrochloride) | 130717-51-0 | ↓ | –2.03 | 3.79 | selective inhibitor of COX-1 |
| TLCK hydrochloride | 4238-41-9 | ↑ | 5.69 | 2.18 | nonselective proteinase inhibitor |
| 63155-80-6 | ↑ | 2.89 | 6.29 | amino-acyl endocannabinoid | |
| thio-miltefosine | 943022-11-5 | ↑ | 2.78 | 4.47 | analogue of miltefosine, an inhibitor of phosphocholine cytidylyl transferase (CTP) with antimetastatic properties |
| 2- | 78858-44-3 | ↑ | 2.68 | 3.49 | synthetic platelet activating factor analogue |
| 1071-37-0 | ↑ | 2.57 | 0.77 | potent inhibitor of nitric oxide synthase | |
| arachidonoyl-2′-fluoroethylamide | 166100-37-4 | ↑ | 2.38 | 6.88 | analogue of anandamide that binds cannabinoid receptors |
| methylcarbamyl PAF C-16 | 91575-58-5 | ↑ | 2.20 | 3.46 | stable analogue of platelet activating factor C-16 |
| MK-886 | 118414-82-7 | ↑ | 2.10 | 8.11 | amino-acyl endocannabinoid |
Abbreviations: 2CAY10444, 2-undecyl-thiazolidine-4-carboxylic acid; FR122047, 1-[[4,5-bis(4-methoxyphenyl)-2-thiazolyl]carbonyl]-4-methyl-piperazine, monohydrochloride; MK-886, 1-[(4-chlorophenyl)methyl]-3-[(1,1-dimethylethyl)thio]-α,α-dimethyl-5-(1-methylethyl)-1H-indole-2-propanoic acid.
As reported in the Cayman product information.